WHO: COVID-19 neither manipulated nor constructed

Geneva: According to World Health Organisation(WHO), All available evidence to date suggests that the novel coronavirus has a natural animal origin and was not a manipulated or constructed virus.

The novel coronavirus was identified in early January and its genetic sequence shared publicly on January 11-12, the WHO noted. The full genetic sequence of the novel coronavirus from the early human cases and the sequences of many other viruses isolated from human cases from China and all over the world showed that the novel coronavirus has an ecological origin in bat populations, according to the world health body.

Although the intermediate animal host has not been identified, all available evidence indicated the novel coronavirus has a zoonotic source, the WHO said,.To better understand the source of the outbreak in China, a number of investigations are currently underway or planned.

Till Friday morning, the global number of coronavirus cases stood at 2,708,470, with 190,788 deaths.

  • Related Posts

    MedTech Zone AMTZ Puts Vizag on the Science Map of India

    Vizag Science &Technology Cluster rated as one of the India’s Strategic Innovation Hubs Visakhapatnam, June 28 – In a significant boost to Vizag’s growing scientific stature, the Andhra Pradesh MedTech…

    • Health
    • June 11, 2025
    • 514 views
    Doctors trialling ‘poo pills’ to flush out dangerous superbugs

    UK doctors are attempting to clear dangerous superbug infections using “poo pills” containing freeze-dried faeces. The stool samples come from healthy donors and are packed with good bacteria. Early data…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    India’s Glenmark Pharma unit, AbbVie sign exclusive licensing pact

    India’s Glenmark Pharma unit, AbbVie sign exclusive licensing pact

    Very Arty Surgery for Weight Loss by SSI Mantra, World’s First

    Very Arty Surgery for Weight Loss by SSI Mantra, World’s First

    Pills & Profits: Can India’s pharma sector handle Trump’s planned 200% tariff dose?

    Pills & Profits: Can India’s pharma sector handle Trump’s planned 200% tariff dose?

    Novartis wins approval for first malaria drug for newborns and babies

    Novartis wins approval for first malaria drug for newborns and babies